Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative

MLA

Cuppens, T., et al. “Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.” Clinical Cancer Research, 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1284161375&authtype=sso&custid=ns315887.

APA

Cuppens, T., Annibali, D., Coosemans, A., Trovik, J., Haar, N. T., Colas, E., Garcia-Jimenez, A., Vijver, K. van der, Kruitwagen, R. P., Brinkhuis, M., Zikan, M., Dundr, P., Huvila, J., Carpen, O., Haybaeck, J., Moinfar, F., Salvesen, H. B., Stukan, M., Mestdagh, C., … Amant, F. (2017). Potential Targets’ Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative. Clinical Cancer Research.

Chicago

Cuppens, T., D. Annibali, A. Coosemans, J. Trovik, N. Ter Haar, E. Colas, A. Garcia-Jimenez, et al. 2017. “Potential Targets’ Analysis Reveals Dual PI3K/MTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.” Clinical Cancer Research. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1284161375&authtype=sso&custid=ns315887.